Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target ...

In March 2026, Insmed reported positive Phase 3b ENCORE results showing ARIKAYCE added to standard multidrug therapy improved symptoms and culture conversion in patients with MAC lung disease who were ...

Insmed remains a Buy, with an enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Learn ...

Investing.com - 美银证券将Insmed(纳斯达克股票代码:INSM)的目标价从211美元上调至213美元,同时维持买入评级。新目标价与华尔街的看涨情绪一致,分析师维持强烈买入共识,目标价区间为166美元至241美元。该股在过去一年中实现了70%的回报,尽管目前交易价格低于其52周高点212.75美元。 该公司援引了ENCORE的积极顶线结果,这是Insmed的3b期试验,评估Ari ...

Investing.com - 杰富瑞将Insmed Incorporated(纳斯达克股票代码:INSM)的目标价从228美元上调至230美元,同时维持对该股的买入评级。新目标价与华尔街的看涨共识一致,分析师维持强力买入评级,目标价区间为166美元至241美元。该股目前交易价格为144.99美元,尽管InvestingPro数据显示,相对于其公允价值估计,股价可能被高估。 该公司在Arikayc ...

Insmed (INSM) stock is flashing a historically bullish signal on the charts, and options may be the right way to play it ...

Investors in Insmed Inc (Symbol: INSM) saw new options become available today, for the December 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed today and set a price target of $206.00. According to TipRanks, Suvannavejh is a 5-star analyst with an average return of ...

Investors in Insmed Inc (Symbol: INSM) saw new options begin trading today, for the July 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the ...

Wells Fargo analyst Tiago Fauth assigned a Buy rating to Insmed today and set a price target of $175.00. Claim 30% Off TipRanks Premium. Unlock hedge fund-level data and powerful ...